Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

INVECTA

Financiado

Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Ap...

Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting the... ver más

30/11/2027

RBI

198K€

Presupuesto del proyecto: 198K€

Líder del proyecto

RUDER BOSKOVIC INSTITUTE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-22

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2022-SE-01-01: MSCA Staff Exchanges 2022

I+D

Cerrada hace 1 año

0% 100%

6 Participantes

RBI

59.80K€ | Lider

CSIC

50.60K€ | Participante

ACCESSION THERAPEUTICS LIMIT...

N.D. | Participante

46.00K€ | Participante

Proyectos interesantes

iAds Intelligent design of adenovirus vectors (iAds) 3M€ Cerrado

BFU2013-41249-P ESTRUCTURA DE ADENOVIRUS DE ESPECIES Y GENEROS POCO CARACTER... 121K€ Cerrado

BIO2015-68990-REDT RED ESPAÑOLA DE ADENOVIRUS: DESDE LA BIOLOGIA BASICA A LA NA... 31K€ Cerrado

PTQ-09-02-01959 MEJORA DE LOS MÉTODOS DE PRODUCCIÓN DE VECTORES ADENOVIRALES... 24K€ Cerrado

BIO2008-03713 CARACTERIZACION FUNCIONAL Y MANIPULACION DE LA ENVUELTA EXTE... 109K€ Cerrado

SAF2012-39504 MECANISMOS DE ESTABILIZACION Y CONTROL DE LA EXPRESION GENIC... 94K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 50 meses Fecha Inicio: 2023-09-22
Fecha Fin: 2027-11-30

Líder del proyecto

RUDER BOSKOVIC INSTITUTE

TRL 4-5

Presupuesto del proyecto 198K€

Descripción del proyecto Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establishing foundation for long term collaboration. As the use of adenoviral based platforms becomes widespread there is a pressing need to develop protocols and methodologies to define the full complement of adenovirus-host interactions, the adenoviral interactome, that may limit efficacy and compromise safety. Within INVECTA we aim to increase our understanding of novel low seroprevalence adenovirus vectors with respect to infectivity, structure, stability, receptor usage, tropism, and the interaction with the blood and immune system. This knowledge will allow us to evaluate novel low seroprevalence vectors at the pre-clinical level in areas of unmet clinical need, namely cancer gene therapy and vaccination. INVECTA presents an interdisciplinary and intersectoral network in basic and translational adenovirus research which will foster transfer of knowledge, skills and technology, as well as enable training in the field of basic and applicative adenovirus biology. To maximize knowledge sharing, INVECTA will second researchers within consortium, organize internal workshops and training sessions, and strongly encourage participation in specialized workshops, schools and conferences according to the open science model.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores